CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
2.350
+0.070 (3.07%)
Sep 5, 2025, 2:46 PM - Market open
CASI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 31.56 | 28.54 | 33.88 | 43.11 | 30.17 | 15.14 | Upgrade | |
Revenue Growth (YoY) | 36.64% | -15.77% | -21.41% | 42.89% | 99.25% | 266.52% | Upgrade |
Cost of Revenue | 18.61 | 17.39 | 13.83 | 15.83 | 12.56 | 9.51 | Upgrade |
Gross Profit | 12.95 | 11.15 | 20.05 | 27.28 | 17.61 | 5.63 | Upgrade |
Selling, General & Admin | 45.49 | 41.44 | 41.84 | 37.78 | 38.41 | 27.48 | Upgrade |
Research & Development | 8.85 | 8.92 | 9.86 | 16 | 14.42 | 11.47 | Upgrade |
Other Operating Expenses | -0 | -0 | -6.37 | - | - | - | Upgrade |
Operating Expenses | 54.34 | 50.36 | 45.33 | 53.77 | 52.83 | 38.95 | Upgrade |
Operating Income | -41.39 | -39.21 | -25.28 | -26.49 | -35.22 | -33.31 | Upgrade |
Interest Expense | -0.93 | -0.87 | -0.02 | -0.06 | - | -0 | Upgrade |
Interest & Investment Income | 0.4 | 0.54 | 0.63 | 0.19 | 0.32 | 0.87 | Upgrade |
Earnings From Equity Investments | -3.36 | -1.19 | -0.05 | -0.85 | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.78 | -0.19 | 0.2 | 3.24 | 0.32 | -1.26 | Upgrade |
Other Non Operating Income (Expenses) | 0.05 | 0.19 | 0.76 | 0.04 | 0.09 | 0.08 | Upgrade |
EBT Excluding Unusual Items | -46.02 | -40.74 | -23.75 | -23.93 | -34.49 | -33.62 | Upgrade |
Gain (Loss) on Sale of Investments | -0.15 | 1.7 | -2.59 | -3.57 | 4.8 | 4.32 | Upgrade |
Gain (Loss) on Sale of Assets | -0.02 | 0.48 | - | -2.06 | -0.07 | 1.15 | Upgrade |
Asset Writedown | -0.7 | -0.7 | - | -8.72 | - | -1.54 | Upgrade |
Other Unusual Items | - | - | - | - | 0.47 | - | Upgrade |
Pretax Income | -46.89 | -39.26 | -26.34 | -38.28 | -35.84 | -47.51 | Upgrade |
Income Tax Expense | - | - | -0.08 | 1.98 | - | - | Upgrade |
Earnings From Continuing Operations | -46.89 | -39.26 | -26.26 | -40.26 | -35.84 | -47.51 | Upgrade |
Minority Interest in Earnings | - | - | -0.68 | -0.76 | -0.81 | -0.78 | Upgrade |
Net Income | -46.89 | -39.26 | -26.94 | -41.01 | -36.65 | -48.29 | Upgrade |
Preferred Dividends & Other Adjustments | - | - | 0.02 | - | - | - | Upgrade |
Net Income to Common | -46.89 | -39.26 | -26.96 | -41.01 | -36.65 | -48.29 | Upgrade |
Shares Outstanding (Basic) | 16 | 15 | 13 | 14 | 14 | 11 | Upgrade |
Shares Outstanding (Diluted) | 16 | 15 | 13 | 14 | 14 | 11 | Upgrade |
Shares Change (YoY) | 21.99% | 14.82% | -2.10% | 0.27% | 23.23% | 15.12% | Upgrade |
EPS (Basic) | -2.87 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | Upgrade |
EPS (Diluted) | -2.87 | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | Upgrade |
Free Cash Flow | - | -29.45 | -20.17 | -26.7 | -35.79 | -27.39 | Upgrade |
Free Cash Flow Per Share | - | -1.92 | -1.51 | -1.96 | -2.63 | -2.48 | Upgrade |
Gross Margin | 41.03% | 39.06% | 59.19% | 63.28% | 58.38% | 37.20% | Upgrade |
Operating Margin | -131.12% | -137.41% | -74.62% | -61.45% | -116.74% | -220.02% | Upgrade |
Profit Margin | -148.56% | -137.57% | -79.58% | -95.14% | -121.50% | -318.92% | Upgrade |
Free Cash Flow Margin | - | -103.19% | -59.54% | -61.94% | -118.63% | -180.87% | Upgrade |
EBITDA | -39.76 | -36.88 | -21.54 | -24.07 | -33.4 | -31.35 | Upgrade |
EBITDA Margin | -125.97% | -129.24% | -63.58% | -55.84% | -110.72% | -207.08% | Upgrade |
D&A For EBITDA | 1.63 | 2.33 | 3.74 | 2.42 | 1.82 | 1.96 | Upgrade |
EBIT | -41.39 | -39.21 | -25.28 | -26.49 | -35.22 | -33.31 | Upgrade |
EBIT Margin | -131.12% | -137.41% | -74.62% | -61.45% | -116.74% | -220.02% | Upgrade |
Revenue as Reported | 28.54 | 28.54 | 33.88 | 43.11 | 30.17 | 15.14 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.